Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 | P35367 | 13/20 | 0.66 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | USP2 | O75604 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19924890 | 0.90 | HRH1 (0.74) | HRH1KCNH2KDM4EUSP2POLB | |
| SCHEMBL9260913 | 0.86 | HRH1 (0.51) | HRH1KCNH2KDM4ECHRM1 | |
| SCHEMBL28758269 | 0.85 | HRH1 (0.67) | HRH1KCNH2KDM4EUSP2POLB | |
| SCHEMBL31632780 | 0.85 | KDM4E (0.47) | HRH1KDM4EUSP2POLBALDH1A1 | |
| SCHEMBL3779989 | 0.83 | HTR2B (0.61) | KDM4E | |
| SCHEMBL14198337 | 0.82 | HRH1 (0.80) | HRH1KCNH2KDM4EPDE10ACHRM1 | |
| SCHEMBL17888852 | 0.81 | HRH1 (0.82) | HRH1KCNH2USP2POLBCYP2D6 | |
| SCHEMBL19770379 | 0.81 | HRH1 (0.95) | HRH1KCNH2 | |
| SCHEMBL7954887 | 0.81 | KDM4E (0.47) | HRH1KDM4EALDH1A1 | |
| SCHEMBL31632781 | 0.80 | OPRM1 (0.57) | KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112110892-A | Preparation method of bilastine important intermediate | 北京万全德众医药生物技术有限公司 | 2020-12-22 | — | — | CN | claimed |
| CN-114591291-B | Bilastine intermediate compound and preparation method thereof | 鲁南制药集团股份有限公司 | 2025-06-17 | — | — | CN | disclosed |
| CN-114591292-B | Bilastine intermediate compounds | 鲁南制药集团股份有限公司 | 2025-06-17 | — | — | CN | disclosed |
| CN-112110892-A | Preparation method of bilastine important intermediate | 北京万全德众医药生物技术有限公司 | 2020-12-22 | — | — | CN | disclosed |
| US-8633223-B2 | Process for preparation of 2-methyl-2′-phenylpropionic acid derivatives and novel intermediate compounds | YUHAN CORPORATION (KR) | 2014-01-21 | — | — | US | disclosed |
| US-8487106-B2 | Process for preparation of 2-methyl-2′-phenylpropionic acid derivatives and novel intermediate compounds | YUHAN CORPORATION (KR) | 2013-07-16 | — | — | US | disclosed |
| US-20130116466-A1 | PROCESS FOR PREPARATION OF 2-METHYL-2'-PHENYLPROPIONIC ACID DERIVATIVES AND NOVEL INTERMEDIATE COMPOUNDS | YUHAN CORPORATION (KR) | 2013-05-09 | — | — | US | disclosed |
| US-20130116439-A1 | PROCESS FOR PREPARATION OF 2-METHYL-2'-PHENYLPROPIONIC ACID DERIVATIVES AND NOVEL INTERMEDIATE COMPOUNDS | YUHAN CORPORATION (KR) | 2013-05-09 | — | — | US | disclosed |
| US-8367704-B2 | Process for preparation of 2-methyl-2′ phenylpropionic acid derivatives and novel intermediate compounds | YUHAN CORPORATION (KR) | 2013-02-05 | — | — | US | disclosed |
| US-20110009636-A1 | PROCESS FOR THE PREPARATION OF 2-METHYL-2'-PHENYLPROPIONIC ACID DERIVATIVES AND NOVEL INTERMEDIATE COMPOUNDS | YUHAN CORPORATION (KP) | 2011-01-13 | — | — | US | disclosed |
| EP-2240464-A2 | PROCESS FOR PREPARATION OF 2-METHYL-2´-PHENYLPROPIONIC ACID DERIVATIVES AND NOVEL INTERMEDIATE COMPOUNDS | Yuhan Corporation (KR) | 2010-10-20 | — | — | EP | disclosed |
| WO-2009102155-A2 | PROCESS FOR PREPARATION OF 2-METHYL-2´-PHENYLPROPIONIC ACID DERIVATIVES AND NOVEL INTERMEDIATE COMPOUNDS | YUHAN CORPORATION (KR) | 2009-08-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110009636-A1 | PROCESS FOR THE PREPARATION OF 2-METHYL-2'-PHENYLPROPIONIC ACID DERIVATIVES AND NOVEL INTERMEDIATE COMPOUNDS | HRH4, HCAR2, HRH1 | HRH1 3/4885KCNH2 945/4885KDM4E 767/4885 |
| US-20130116439-A1 | PROCESS FOR PREPARATION OF 2-METHYL-2'-PHENYLPROPIONIC ACID DERIVATIVES AND NOVEL INTERMEDIATE COMPOUNDS | HRH2, HRH4, HNMT | HRH1 4/4885KCNH2 711/4885KDM4E 466/4885 |
| US-20130116466-A1 | PROCESS FOR PREPARATION OF 2-METHYL-2'-PHENYLPROPIONIC ACID DERIVATIVES AND NOVEL INTERMEDIATE COMPOUNDS | HRH1, HRH2, HRH4 | HRH1 1/4885KCNH2 1065/4885KDM4E 815/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.